170 Results for "

PD-L1 antibody

" in MedChemExpress (MCE) Product Catalog:
Products (170)

170 Results for "PD-L1 antibody" in MCE Product Catalog:

42
42 Publications Verification
Cat. No.: HY-P9904
CAS No.: 1380723-44-3
Synonyms: MPDL3280A; RG-7446; RO-5541267

Research Areas:  

Cancer

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-P9902
CAS No.: 1374853-91-4
Synonyms: MK-3475; Lambrolizumab

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-P99144

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-P9903
CAS No.: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106

Target:  

PD-1/PD-L1

Research Areas:  

Infection Cancer

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-P99145

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Purity:  96.02%

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9971
CAS No.: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P990679

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Rat IgG2a kappa, Isotype Control is a monoclonal antibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology. Rat IgG2a kappa, an isotype control, can be used as an isotype control for Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144), Anti-Mouse CD11a/LFA-1α Antibody (M17/4) (HY-P990801), and Anti-Mouse IL-2 Antibody (S4B6-1) (HY-P990796) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99048
CAS No.: 2072873-06-2
Synonyms: IBI308

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99052
CAS No.: 1858168-59-8
Synonyms: BGB-A317
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P990824

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P990173

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9993
CAS No.: 2411580-63-5
Synonyms: LY-3462817

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99100
CAS No.: 2556646-63-8
Synonyms: CTL-002

Research Areas:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99144A

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99419
CAS No.: 2253937-12-9
Synonyms: GEN1046

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
loading...
    loading...